Drug resistance in cancer - Searching for mechanisms, markers and therapeutic agents

Expert Opinion on Drug Metabolism and Toxicology

Volumn 3, Issue 6, 2007, Pages 805-817

  O'Connor, Robert ^a   Clynes, Martin ^a   Dowling, Paul ^a   O'Donovan, Norma ^a   O'Driscoll, Lorraine ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Cancer chemotherapy; Drug resistance; Multiple drug resistance; Targeted therapy; Tyrosine kinase

Indexed keywords

4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; ANTHRACYCLINE; BEVACIZUMAB; BORTEZOMIB; BREAST CANCER RESISTANCE PROTEIN; CETUXIMAB; CISPLATIN; DASATINIB; DIHYDROFOLIC ACID; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUOROURACIL; GEFITINIB; GLYCOPROTEIN P; IMATINIB; LAPATINIB; LENALIDOMIDE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TAMOXIFEN; TRASTUZUMAB; UNINDEXED DRUG; VATALANIB; VERAPAMIL; VINCA ALKALOID; VINCRISTINE; XENOBIOTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL INTERACTION; CELL STRAIN MCF 7; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE MARKER; DOWN REGULATION; DRUG BINDING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TARGETING; DRUG TRANSPORT; ENZYME ACTIVITY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LEUKEMIA; LUNG ADENOCARCINOMA; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; NEOPLASM; NONHUMAN; PROTEOMICS; REVIEW; TARGET CELL; TRANSPORT KINETICS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 37349021709     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.3.6.805     Document Type: Review

References (103)

1. DEAN M, FOJO T, BATES S: Tumour stem cells and drug resistance. Nat. Rev. Cancer (2005) 5(4):275-284.
2. CLEARY I, DOHERTY G, MORAN E, CLYNES M: The multidrug-resistant human lung tumour cell line, DLKP-A10, expresses novel drug accumulation and sequestration systems. Biochem. Pharmacol. (1997) 53(10):1493-1502.
3. STEINER E, HOLZMANN K, ELBLING L, MICKSCHE M, BERGER W: Cellular functions of vaults and their involvement in multidrug resistance. Curr. Drug Targets (2006) 7(8):923-934.
4. CHEN KG, VALENCIA JC, LAI B et al.: Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc. Natl. Acad. Sci. USA (2006) 103(26):9903-9907.
5. HEENAN M, O'DRISCOLL L, CLEARY I, CONNOLLY I, CLYNES M: Isolation from a human MDR lung cell line of multiple clonal subpopulations which exhibit significantly different drug resistance. Int. J. Cancer (1997) 71(5):907-915.
6. O'CONNOR R, O'LEARY M, BALLOT J et al.: A Phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemother. Pharmacol. (2007) 59(1):79-87.
7. LEONARD GD. POLGAR O, BATES SE: ABC transporters and inhibitors: new targets, new agents. Curr. Opin. Investig. Drugs (2002) 3(11):1652-1659.
8. JULIANO RL, LING V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biopbys. Acta (1976) 455(1):152-162.
9. CALLAGHAN R, FORD RC, KERR ID: The translocation mechanism of P-glycoprotein. FEBS Lett. (2006) 580(4):1056-1063.
10. OZVEGY-LACZKA C, CSEREPES J, ELKIND NB, SARKADI B: Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist. Updat. (2005) 8(1-2):15-26.
11. COLE SP, BHARDWAJ G, GERLACH J H et al.: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (1992) 258(5088):1650-1654.
12. SARKADI B, OZVEGY-LACZKA C, NEMET K, VARADI A: ABCG2 - a transporter for all seasons. FEBS Lett. (2004) 567(1):116-120.
13. KRUH GD, GUO Y, HOPPER-BORGE E, BELINSKY MG, CHEN ZS: ABCC10, ABCC11, and ABCC12. Pflugers Arch. (2007) 453(5):675-684.
14. BORST P, DE WOLF C, VAN DE WETERING K: Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch. (2007) 453(5):661-673.
15. TUSNADY GE, SARKADI B, SIMON I, VARADI A: Membrane topology of human ABC proteins. FEBS Lett. (2006) 580(4):1017-1022.
16. AMBUDKAR SV, KIMCHI-SARFATY C, SAUNA ZE, GOTTESMAN MM: P-glycoprotein: from genomics to mechanism. Oncogene (2003) 22(47):7468-7485.
17. COLE SP, DEELEY RG: Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol. Sci. (2006) 27(8):438-446.
18. LEONESSA F, CLARKE R: ATP binding cassette transporters and drug resistance in breast cancer. Endocr. Relat. Cancer (2003) 10(1):43-73.
19. PEREZ-TOMAS R: Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem. (2006) 13(16):1859-1876.
20. STEIN WD, BATES SE, FOJO T: Intractable cancers: the many faces of multidrug resistance and the many targets it presents for therapeutic attack. Curr. Drug Targets (2004) 5(4):333-346.
21. BAKER EK, JOHNSTONE RW, ZALCBERG JR, EL-OSTA A: Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene (2005) 24(54):8061-8075.
22. LEONARD GD, FOJO T, BATES SE: The role of ABC transporters in clinical practice. Oncologist (2003) 8(5):411-424.
23. PUSZTAI L, WAGNER P, IBRAHIM N et al.: Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer (2005) 104(4):682-691.
24. CLARKE R, LEONESSA F, TROCK B: Multidrug resistance/P-glycoprotein and breast cancer review and meta-analysis. Semin. Oncol. (2005) 32(6 Suppl. 7):S9-S15.
25. O'CONNOR R: The pharmacology of cancer resistance. Anticancer Res. (2007) 27(3A):1267-1272.
26. KIM RB: Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur. J. Clin. Invest. (2003) 33(Suppl. 2):1-5.
27. SMITH NF, ACHARYA MR, DESAI N, FIGG WD, SPARREBOOM A: Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol. Ther. (2005) 4(8):815-818.
28. KAPP T, MULLER S, GUST R. Dinuclear alkylamine platinum(II) complexes of [1,2-bis(4-fluorophenyl)ethylenediamine] platinum(II): influence of endocytosis and copper and organic cation transport systems on cellular uptake. ChemMedChem (2006) 1(5):560-564.
29. SU Y, ZHANG X, SINKO PJ: Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol. Pharm. (2004) 1(1):49-56.
30. CUI Y, KONIG J, NIES AT et al.: Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma. Lab. Invest. (2003) 83(4):527-538.
31. O'DWYER ME, MAURO MJ, DRUKER BJ: STI571 as a targeted therapy for CML. Cancer Invest. (2003) 21(3):429-438.
32. SLAMON DJ, CLARK GM, WONG SG, LEVIN WJ, ULLRICH A, MCGUIRE WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 235(4785):177-182.
33. DEMONTY G, BERNARD-MARTY C, PUGLISI F, MANCINI I, PICCART M: Progress and new standards of care in the management of HER-2 positive breast cancer. Eur. J. Cancer (2007) 43(3):497-509.
34. GEYER CE, FORSTER J, LINDQUIST D et al.: Lapatinib plus capecitabine for HER2-positiveadvanced breast cancer. N. Engl. J. Med. (2006) 355(26):2733-2743.
35. LYNCH TJ, BELL DW, SORDELLA R et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. (2004) 350(21):2129-2139.
36. PAEZ JG, JANNE PA, LEE JC et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 304(5676):1497-1500.
37. RANIERI G, PATRUNO R, RUGGIERI E, MONTEMURRO S, VALERIO P, RIBATTI D: Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr. Med. Chem. (2006) 13(16):1845-1857.
38. MENDEL DB, LAIRD AD, XIN X et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. (2003) 9(1):327-337.
39. WILHELM SM, CARTER C, TANG L et al.: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. (2004) 64(19):7099-7109.
40. LOMBARDO LJ, LEE FY, CHEN P et al.: Discovery of N- (2-chloro-6-methyl-phenyl)- 2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2- methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. (2004) 47 (27):6658-6661.
41. BURGER H, VAN TOL H, BROK M et al.: Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol. Ther. (2005) 4(7):747-752.
42. THOMAS J, WANG L, CLARK RE, PIRMOHAMED M: Active transport of imatinib into and out of cells: implications for drug resistance. Blood (2004) 104(12):3739-3745.
43. CROSSMAN LC, DRUKER BJ, DEININGER MW, PIRMOHAMED M, WANG L, CLARK RE: hOCT 1 and resistance to imatinib. Blood (2005) 106(3):1133-1134.
44. LEGGAS M, PANETTA JC, ZHUANG Y et al.: Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res. (2006) 66(9):4802-4807.
45. + cell lines. Ann. Oncol. (2006) 17(S9):57.
46. VILORIA-PETIT AM, KERBEL RS: Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. Int. J. Radiat. Oncol. Biol. Phys. (2004) 58(3):914-926.
47. DEININGER M, BUCHDUNGER E, DRUKER BJ: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood (2005) 105(7):2640-2653.
48. HEINRICH MC, CORLESS CL, BLANKE CD et al.: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol. (2006) 24(29):4764-4774.
49. COOLS J, DEANGELO DJ, GOTLIB J et al.: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. (2003) 348(13):1201-1214.
50. GADZICKI D, VON NEUHOFF N, STEINEMANN D et al.: BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib. Cancer Genet. Cytogenet. (2005) 159(2):164-167.
51. PAO W, WANG TY, RIELY GJ et al.: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. (2005) 2(1):E17.
52. PAO W, MILLER V, ZAKOWSKI M et al.: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA (2004) 101(36):13306-13311.
53. PAO W, MILLER VA, POLITI KA et al.: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoSMed. (2005) 2(3):E73.
54. LIEVRE A, BACHET JB, LE CORRE D et al.: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. (2006) 66(8):3992-3995.
55. PERERA RM, NARITA Y, FURNARI FB et al.: Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin. Cancer Res. (2005) 11(17):6390-6399.
56. NAHTA R, ESTEVA FJ: Herceptin: mechanisms of action and resistance. Cancer Lett. (2006) 232(2):123-138.
57. NAHTA R, TAKAHASHI T, UENO NT HUNG MC, ESTEVA FJ: P27(kip 1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. (2004) 64(11):3981-3986.
58. NAGATA Y, LAN KH, ZHOU X et al.: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 6(2):117-127.
59. LU Y, ZI X, POLLAK M: Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int. J. Cancer (2004) 108(3):334-341.
60. NAHTA R, YUAN LX, ZHANG B, KOBAYASHI R, ESTEVA FJ: Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. (2005) 65(23):11118-11128.
61. SMITH BL, CHIN D, MALTZMAN W, CROSBY K, HORTOBAGYI GN, BACUS SS: The efficacy of herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins. Br. J. Cancer (2004) 91(6):1190-1194.
62. XIA W, BACUS S, HEGDE P et al.: A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc. Natl. Acad. Sci. USA (2006) 103(20):7795-7800.
63. CAPPUZZO F, TOSCHI I, TALLINI G et al.: Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann. Oncol. (2006) 17(7):1120-1127.
64. MORGILLO F, KIM WY, KIM ES, CIARDIELLO F, HONG WK, LEE HY: Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin. Cancer Res. (2007) 13(9):2795-2803.
65. JONES HE, GODDARD L, GEE JM et al.: Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr. Relat. Cancer (2004) 11(4):793-814.
66. SHAH NP, TRAN C, LEE FY, CHEN P, NORRIS D, SAWYERS CL: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 305(5682):399-401.
67. HWANG JJ, GHOBRIAL IM, ANDERSON KC: New frontiers in the treatment of multiple myeloma. Scientific World Journal (2006) 6:1475-1503.
68. MITSIADES CS, MITSIADES NS, MUNSHI NC, RICHARDSON PG, ANDERSON KC: The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur. J. Cancer (2006) 42(11):1564-1573.
69. CARRASCO DR, SUKHDEO K, PROTOPOPOVA M et al.: The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell (2007) 11(4):349-360.
70. HIDESHIMA T, BERGSAGEL PL, KUEHL WM, ANDERSON KC: Advances in biology of multiple myeloma: clinical applications. Blood (2004) 104(3):607-618.
71. MULLIGAN G, MITSIADES C, BRYANT B et al.: Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2007) 109(8):3177-3188.
72. CHAUHAN D, HIDESHIMA T, ANDERSON KC: A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br. J. Cancer (2006) 95(8):961-965.
73. ANDERSON KC: Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp. Hematol. (2007) 35(4 Suppl. 1): 155-162.
74. GEHRMANN MI, FENSELAU C, HATHOUT Y: Highly altered protein expression profile in the adriamycin resistant MCF-7 cell line. J. Proteome Res. (2004) 3(3):403-409.
75. SHIN YK, YOO BC, CHANG HJ et al.: Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res. (2005) 65(8):3162-3170.
76. BESADA V, DIAZ M, BECKER M, RAMOS Y, CASTELLANOS-SERRA L, FICHTNER I: Proteomics of xenografted human breast cancer indicates novel targets related to tamoxifen resistance. Proteomics (2006) 6(3):1038-1048.
77. VERRILLS NM, LIEM NI, LIAW TY, HOOD BD, LOCK RB, KAVALLARIS M: Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukaemia - an in vivo study. Proteomics (2006) 6(5):1681-1694.
78. LAUTEN M, SCHRAUDER A, KARDINAL C et al.: Unsupervised proteome analysis of human leukaemia cells identifies the valosin-containing protein as a putative marker for glucocorticoid resistance. Leukemia (2006) 20(5):820-826.
79. BRITTEN RA, HARDY C, VLAHOU A, GREGORY B, GIRI PS, DRAKE R: Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells. Oncol. Rep. (2005) 14(5):1323-1330.
80. STEWART JJ, WHITE JT, YAN X et al.: Proteins associated with cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol. Cell Proteomics (2006) 5(3):433-443.
81. JOYCE H, BRAY I, CLYNES M: RNA interference with SiRNA. Cancer Genomics Proteomics (2006) 3:127-136.
82. KHAN AU: Ribozyme: a clinical tool. Clin. Chim. Acta (2006) 367(1-2):20-27.
83. WACHECK V, ZANGEMEISTER-WITTKE U: Antisense molecules for targeted cancer therapy. Crit. Rev. Oncol. Hematol. (2006) 59(1):65-73.
84. SCHERF U, ROSS DT, WALTHAM M et al.: A gene expression database for the molecular pharmacology of cancer. Nat. Genet. (2000) 24(3):236-244.
85. STAUNTON JE, SLONIM DK, COLLER HA et al.: Chemosensitivity prediction by transcriptional profiling. Proc. Natl. Acad. Sci. USA (2001) 98(19):10787-10792.
86. KUDOH K, RAMANNA M, RAVATN R et al.: Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. (2000) 60(15):4161-4166.
87. SORLIE T, PEROU CM, TIBSHIRANI R et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA (2001) 98(19):10869-10874.
88. KAKLAMANI VG, GRADISHAR WJ: Gene expression in breast cancer. Curr. Treat. Options Oncol. (2006) 7(2):123-128.
89. TROESTER MA, HOADLEY KA, SORLIE T et al.: Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res. (2004) 64(12):4218-4226.
90. WHITESIDE MA, CHEN DT, DESMOND RA, ABDULKADIR SA, JOHANNING GL: A novel time-course cDNA microarray analysis method identifies genes associated with the development of cisplatin resistance. Oncogene (2004) 23(3):744-752.
91. PARK JS, YOUNG YOON S, KIM JM, YEOM YI, KIM YS, KIM NS: Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. Cancer Lett. (2004) 214(1):19-33.
92. HERNANDEZ-VARGAS H, BALLESTAR E, CARMONA-SAEZ P et al.: Transcriptional profiling of MCF7 breast cancer cells in response to 5-fluorouracil: relationship with cell cycle changes and apoptosis, and identification of novel targets of p53. Int. J. Cancer (2006) 119(5):1164-1175.
93. NAKATANI K, NAKAMURA M, UZAWA K et al.: Establishment and gene analysis of a cisplatin-resistant cell lineSa-3R, derived from oral squamous cell carcinoma. Oncol. Rep. (2005) 13(4):709-714.
94. GOTO T, TAKANO M, SAKAMOTO M et al.: Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers. Oncol. Rep. (2006) 15(5):1265-1271.
95. RICKARDSON L, FRYKNAS M, DHAR S et al.: Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles. Br. J. Cancer (2005) 93(4):483-492.
96. GILLET JP, EFFERTH T, STEINBACH D et al.: Microarray-based detection of multidrug resistance in human tumor cells by expression profiling of ATP-binding cassette transporter genes. Cancer Res. (2004) 64(24):8987-8993.
97. KIHARA C, TSUNODA T, TANAKA T et al.: Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res. (2001) 61(17):6474-6479.
98. ROSENWALD A, WRIGHT G, CHAN WC et al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. (2002) 346(25):1937-1947.
99. REIS-FILHO JS, WESTBURY C, PIERGA JY: The impact of expression profiling on prognostic and predictive testing in breast cancer. J. Clin. Pathol. (2006) 59(3):225-231.
100. BUCHHOLZ TA, STIVERS DN, STEC J et al.: Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J. (2002) 8(6):461-468.
101. SOTIRIOU C, POWLES TJ, DOWSETT M et al.: Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. (2002) 4(3): R3.
102. CHANG JC, WOOTEN EC, TSIMELZON A et al.: Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet (2003) 362(9381):362-369.
103. AYERS M, SYMMANS WF, STEC J et al.: Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J. Clin. Oncol. (2004) 22(12):2284-2293.